1 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow CC-223: new trials by email Literature Review of CC-223 trials Research Report on CC-223
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma CC-223 - Multiple Myeloma, Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Celgene | 226 | 2010-07-20 | 2022-12-13 |
Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Glioblastoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Multiple Myeloma (1)
Celgene (1)
France (1) · Spain (1) · United Kingdom (1) · United States (1)